OncoMatch/Clinical Trials/NCT06116682
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Is NCT06116682 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Amivantamab for lung non-small cell carcinoma.
Treatment: Amivantamab — This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MET amplification
MET amplification determined by FMI tissue-based next generation sequencing (NGS) assay
Excluded: EGFR sensitizing mutation
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations
Excluded: EGFR T790M
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... EGFR T790M mutation
Excluded: MET exon 14 skipping
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... MET Exon-14 skipping mutant NSCLC
Excluded: ALK fusion
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... ALK gene fusion
Excluded: ROS1 rearrangement
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... ROS1 gene rearrangement
Excluded: RET rearrangement
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... RET gene rearrangement
Excluded: NTRK1 rearrangement
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... NTRK rearrangement
Excluded: NTRK2 rearrangement
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... NTRK rearrangement
Excluded: NTRK3 rearrangement
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... NTRK rearrangement
Excluded: HER2 (ERBB2) mutation
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... HER2 mutation
Excluded: KRAS activating mutation
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... KRAS activating mutations
Excluded: BRAF V600E
Participants must not have other known actionable oncogenic alterations, such as (but not limited to) ... BRAF V600E mutation
Disease stage
Required: Stage IV
Stage IV or recurrent Non-Small Cell Lung Cancer
Performance status
ZUBROD 0–2
Prior therapy
Must have received: systemic therapy — stage iv or recurrent nsclc
Cannot have received: met tyrosine kinase inhibitor (tepotinib, capmatinib, crizotinib)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^3/uL; Hemoglobin ≥ 10.0 g/dL; Platelets ≥ 75 x 10^3/uL
Kidney function
serum creatinine ≤ institutional ULN or calculated creatinine clearance ≥ 45 mL/min
Liver function
Total bilirubin ≤ 1.5 x institutional ULN unless history of Gilbert's disease (then ≤ 5 x ULN); AST and ALT ≤ 3 × institutional ULN (≤ 5 x ULN with liver metastasis)
Cardiac function
Participants with cardiac disease or history of cardiotoxic agents must be NYHA class 2B or better
Absolute neutrophil count ≥ 1.5 x 10^3/uL; Hemoglobin ≥ 10.0 g/dL; Platelets ≥ 75 x 10^3/uL; Total bilirubin ≤ 1.5 x institutional ULN unless history of Gilbert's disease (then ≤ 5 x ULN); AST and ALT ≤ 3 × institutional ULN (≤ 5 x ULN with liver metastasis); serum creatinine ≤ institutional ULN or calculated creatinine clearance ≥ 45 mL/min; NYHA class 2B or better if cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro, Arkansas
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- Sutter Auburn Faith Hospital · Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus · Berkeley, California
- Palo Alto Medical Foundation-Fremont · Fremont, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06116682 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior met tyrosine kinase inhibitor disqualifies patients from enrollment.
Does this trial require MET?
Yes, MET amplification is a required biomarker for enrollment.
Are patients with EGFR alterations eligible?
No. EGFR sensitizing mutation is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR T790M is an exclusion criterion.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages